Dose-Volume Histogram Parameters and Quality of Life in Patients with Prostate Cancer Treated with Surgery and High-Dose Volumetric-Intensity-Modulated Arc Therapy to the Prostate Bed.

dose constraints dose-volume histogram prostate bed prostate cancer quality of life radiotherapy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
30 Jun 2023
Historique:
received: 19 05 2023
revised: 28 06 2023
accepted: 28 06 2023
medline: 14 7 2023
pubmed: 14 7 2023
entrez: 14 7 2023
Statut: epublish

Résumé

Prostate bed radiotherapy (RT) is a major affecter of patients' long-term quality of life (QoL). To ensure the best possible outcome of these patients, dose constraints are key for optimal RT planning and delivery. However, establishing refined dose constraints requires access to patient-level data. Therefore, we aimed to provide such data on the relationship between OAR and gastrointestinal (GI) as well as genitourinary (GU) QoL outcomes of a homogenous patient cohort who received dose-intensified post-operative RT to the prostate bed. Furthermore, we aimed to conduct an exploratory analysis of the resulting data. Patients who were treated with prostate bed RT between 2010 and 2020 were inquired about their QoL based on the Expanded Prostate Cancer Index Composite (EPIC). Those (n = 99) who received volumetric arc therapy (VMAT) of at least 70 Gy to the prostate bed were included. Dose-volume histogram (DVH) parameters were gathered and correlated with the EPIC scores. The median age at the time of prostate bed RT was 68.9 years, and patients were inquired about their QoL in the median 2.3 years after RT. The median pre-RT prostate-specific antigen (PSA) serum level was 0.35 ng/mL. The median duration between surgery and RT was 1.5 years. The median prescribed dose to the prostate bed was 72 Gy. A total of 61.6% received prostate bed RT only. For the bladder, the highest level of statistical correlation ( Specific dose constraints for bladder volumes receiving low doses seem desirable for the further optimization of prostate bed RT. This may be particularly relevant in the context of the aspiration of establishing focal RT of prostate cancer and its local recurrences. Our comprehensive dataset may aid future researchers in achieving these goals.

Identifiants

pubmed: 37444564
pii: cancers15133454
doi: 10.3390/cancers15133454
pmc: PMC10340614
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S3-9
pubmed: 20171515
Health Qual Life Outcomes. 2018 Feb 20;16(1):36
pubmed: 29458434
Pract Radiat Oncol. 2023 Mar-Apr;13(2):e149-e165
pubmed: 36522277
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1655-60
pubmed: 22572080
BMJ Open. 2022 Nov 8;12(11):e068580
pubmed: 36351720
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S10-9
pubmed: 20171502
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
Clin Transl Radiat Oncol. 2019 Apr 01;18:68-73
pubmed: 31341979
Lancet Oncol. 2020 Oct;21(10):1331-1340
pubmed: 33002437
J Urol. 2011 Sep;186(3):865-72
pubmed: 21788038
Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1514-1532
pubmed: 30125635
Eur Urol Oncol. 2022 Apr;5(2):146-152
pubmed: 35074282
BJU Int. 2007 Jun;99(6):1376-9
pubmed: 17428247
Cancer Treat Rev. 2021 Apr;95:102176
pubmed: 33743409
Adv Radiat Oncol. 2018 May 08;3(3):339-345
pubmed: 30202803
Eur Urol. 2018 Jul;74(1):107-114
pubmed: 29233664
Int J Radiat Oncol Biol Phys. 2020 May 1;107(1):143-151
pubmed: 32004582
Eur Urol. 2021 Sep;80(3):306-315
pubmed: 34140144
Lancet. 2022 May 14;399(10338):1886-1901
pubmed: 35569466
Int J Radiat Oncol Biol Phys. 2023 May 6;:
pubmed: 37150260
Radiother Oncol. 2022 Feb;167:165-171
pubmed: 34923034
Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):339-44
pubmed: 24411606
Int J Radiat Oncol Biol Phys. 2021 Dec 1;111(5):1195-1203
pubmed: 34015368
Radiat Oncol. 2017 Jun 16;12(1):99
pubmed: 28622770
J Urol. 1992 Nov;148(5):1549-57; discussion 1564
pubmed: 1279218
Radiother Oncol. 2019 Jun;135:19-24
pubmed: 31015166
Radiother Oncol. 2007 Aug;84(2):121-7
pubmed: 17706307

Auteurs

Luca Hanke (L)

Department of Radiation Oncology, Cantonal Hospital Winterthur, Brauerstrasse 15, 8401 Winterthur, Switzerland.

Hongjian Tang (H)

Department of Radiation Oncology, Cantonal Hospital Winterthur, Brauerstrasse 15, 8401 Winterthur, Switzerland.

Christina Schröder (C)

Department of Radiation Oncology, Cantonal Hospital Winterthur, Brauerstrasse 15, 8401 Winterthur, Switzerland.

Paul Windisch (P)

Department of Radiation Oncology, Cantonal Hospital Winterthur, Brauerstrasse 15, 8401 Winterthur, Switzerland.

Ken Kudura (K)

Department of Nuclear Medicine, Sankt Clara Hospital, Kleinriehenstrasse 30, 4058 Basel, Switzerland.

Mohamed Shelan (M)

Department of Radiation Oncology, Inselspital, University Hospital Bern, Freiburgstrasse 18, 3010 Bern, Switzerland.

André Buchali (A)

Department of Radiation Oncology, University Hospital Ruppin-Brandenburg, Fehrbelliner Strasse 38, 16816 Neuruppin, Germany.

Stephan Bodis (S)

Department of Radiation Oncology, Cantonal Hospital Aarau, Tellstrasse 25, 5001 Aarau, Switzerland.

Robert Förster (R)

Department of Radiation Oncology, Cantonal Hospital Winterthur, Brauerstrasse 15, 8401 Winterthur, Switzerland.

Daniel R Zwahlen (DR)

Department of Radiation Oncology, Cantonal Hospital Winterthur, Brauerstrasse 15, 8401 Winterthur, Switzerland.

Classifications MeSH